Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Suzuki, Satoshi; Sakurai, Daiju; Sakurai, Takeshi; Yonekura, Syuji; Iinuma, Tomohisa; Okuma, Yusuke; Ihara, Fumie; Arai, Toshiyasu; Hanazawa, Toyoyuki; Fukuda-Kawaguchi, Emi; Ishii, Yasuyuki; Okamoto, Yoshitaka

doi:10.1016/j.alit.2019.02.003

Cited by 16 publications

(8 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sublingually administered cationic and neutral liposomes significantly reduced airway eosinophilia compared to unencapsulated OVA. In another study, mice allergic to OVA were given α-galactosylceramide (α-Gal-Cer) liposomes to act as an adjuvant to OVA therapy . Mice were treated with sublingual OVA, liposomes, or the OVA and liposomes for 7 days and then re-evaluated for allergies.…”

Section: Sublingual Drug Deliverymentioning

confidence: 99%

“…In another study, mice allergic to OVA were given αgalactosylceramide (α-Gal-Cer) liposomes to act as an adjuvant to OVA therapy. 36 Mice were treated with sublingual OVA, liposomes, or the OVA and liposomes for 7 days and then re-evaluated for allergies. In the mice with OVA alone, there was reduction in IL-4, IL-5, and IL-13, though there was no significant improvement in allergy symptoms.…”

Section: ■ Sublingual Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine for Drug Delivery throughout the Alimentary Canal

2021

View full text Add to dashboard Cite

The field of nanomedicine continues to grow with new technologies and formulations in development for several disease states. Much research focuses on the use of injectable nanomedicines for treatment of neoplasms; however, there are several formulations in development that use nanotechnology that can be administered enterally for noncancer indications. These nanomedicine treatments have been developed for systemic drug delivery or local drug delivery along the gastrointestinal tract. This Review gives a brief overview of the alimentary canal and highlights new research in nanomedicine in noncancer disease states delivered via enteral routes of administration. Relevant recent research is summarized on the basis of the targeted site of action or absorption, including the buccal, sublingual, stomach, small intestine, and large intestine areas of the alimentary canal. The benefits of nanodrug delivery are discussed as well as barriers and challenges for future development in the field.

show abstract

Section: Sublingual Drug Deliverymentioning

confidence: 99%

Section: ■ Sublingual Drug Deliverymentioning

confidence: 99%

Nanomedicine for Drug Delivery throughout the Alimentary Canal

2021

View full text Add to dashboard Cite

show abstract

“…For SIT, right before each time of nasal instillation with OVA, mice were sublingually administered with 1 mg of OVA in 20 μl of PBS during sensitization. To prevent immediate swallowing of the allergen, mice were held on the back for 1 min [12]. 3 Journal of Immunology Research 2.3.…”

Section: Development Of An Ar Mouse Model and Specificmentioning

confidence: 99%

Short-Chain Fatty Acids Promote Immunotherapy by Modulating Immune Regulatory Property in B Cells

Zhou

Xie

Han

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

The dysfunction of regulatory B cells (Breg) may result in immune inflammation such as allergic rhinitis (AR); the underlying mechanism is not fully understood yet. Short-chain fatty acids, such as propionic acid (PA), have immune regulatory functions. This study is aimed at testing a hypothesis that modulates PA production alleviating airway allergy through maintaining Breg functions. B cells were isolated from the blood obtained from AR patients and healthy control (HC) subjects. The stabilization of IL-10 mRNA in B cells was tested with RT-qPCR. An AR mouse model was developed to test the role of PA in stabilizing the IL-10 expression in B cells. We found that the serum PA levels were negatively correlated with the serum Th2 cytokine levels in AR patients. Serum PA levels were positively associated with peripheral CD5+ B cell frequency in AR patients; the CD5+ B cells were also IL-10+. The spontaneous IL-10 mRNA decay was observed in B cells, which was prevented by the presence of PA through activating GPR43. PA counteracted the effects of Tristetraprolin (TTP) on inducing IL-10 mRNA decay in B cells through the AKT/T-bet/granzyme B pathway. Administration of Yupinfeng San, a Chinese traditional medical formula, or indole-3-PA, induced PA production by intestinal bacteria to stabilize the IL-10 expression in B cells, which promoted the allergen specific immunotherapy, and efficiently alleviated experimental AR. In summary, the data show that CD5+ B cells produce IL-10. The serum lower PA levels are associated with the lower frequency of CD5+ B cells in AR patients. Administration with Yupinfeng San or indole-3-PA can improve Breg functions and alleviate experimental AR.

show abstract

“…After re‐challenge with OVA, cervical LN CD4 + T cells elaborated decreased IL‐4, IL‐5, IL‐13, and IL‐17 on both the protein and mRNA level. In contrast, Th1 cytokine production was upregulated and paralleled by the production of increased levels of allergen‐specific IgG and reduced levels of IgE . Bal et al.…”

Section: Liposomes For the Modulation Of Allergic Immune Responsementioning

confidence: 99%

“…After re-challenge with OVA, cervical LN CD4 + T cells elaborated decreased IL-4, IL-5, IL-13, and IL-17 on both the protein and mRNA level. In contrast, Th1 cytokine production was upregulated and paralleled by the production of increased levels of allergen-specific IgG and reduced levels of IgE [129]. Bal et al further increased the immunomodulatory capacity of liposomes by combining the model allergen OVA with the TLR ligands PAM or CpG and encapsulated them into cationic liposomes [130].…”

Section: Liposomes For the Modulation Of Allergic Immune Responsementioning

confidence: 99%

All the small things: How virus‐like particles and liposomes modulate allergic immune responses

et al. 2019

View full text Add to dashboard Cite

Recent years have seen a dramatic increase in the range of applications of virus‐like nanoparticle (VNP)‐ and liposome‐based antigen delivery systems for the treatment of allergies. These platforms rely on a growing number of inert virus‐backbones or distinct lipid formulations and intend to engage the host's innate and/or adaptive immune system by virtue of their co‐delivered immunogens. Due to their particulate nature, VNP and liposomal preparations are also capable of breaking tolerance against endogenous cytokines, Igs, and their receptors, allowing for the facile induction of anti‐cytokine, anti‐IgE, or anti‐FcεR antibodies in the host. We here discuss the “pros and cons” of inducing such neutralizing autoantibodies. Moreover, we cover another major theme of the last years, i.e., the engineering of non‐anaphylactogenic particles and the elucidation of the parameters relevant for the specific trafficking and processing of such particles in vivo. Finally, we put the various technical advances in VNP‐ and liposome‐research into (pre‐)clinical context by referring and critically discussing the relevant studies performed to treat allergic diseases.

show abstract

Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Cited by 16 publications

References 49 publications

Nanomedicine for Drug Delivery throughout the Alimentary Canal

Nanomedicine for Drug Delivery throughout the Alimentary Canal

Short-Chain Fatty Acids Promote Immunotherapy by Modulating Immune Regulatory Property in B Cells

All the small things: How virus‐like particles and liposomes modulate allergic immune responses

Contact Info

Product

Resources

About